Novo Nordisk (NYSE: NVO) was featured in a recent analysis report that discussed rocketing mentions of the company’s Ozempic drug (+86). “Ozempic (made by Novo Nordisk) currently holds a massive brand recognition lead when it comes to…
To read the full report and view the infographic, please visit https://ibn.fm/90nZ5
About Novo Nordisk
Novo Nordisk is a global health care company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Its purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. Novo Nordisk does so by pioneering scientific breakthroughs, expanding access to its medicines and working to prevent and ultimately cure the diseases it treats. Novo Nordisk employs more than 55,000 people in 80 offices around the world and markets its products in 170 countries.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork